

Other version: https://www.sciencedirect.com/science/article/pii/S1552526019300743
![]() |
Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort |
|
Authors | ![]() | |
Published in | Alzheimer's & dementia. 2019, vol. 15, no. 6, p. 817-827 | |
Abstract | A critical and as-yet unmet need in Alzheimer's disease (AD) is the discovery of peripheral small molecule biomarkers. Given that brain pathology precedes clinical symptom onset, we set out to test whether metabolites in blood associated with pathology as indexed by cerebrospinal fluid (CSF) AD biomarkers. | |
Keywords | EMIF-AD — Alzheimer's disease — Dementia — Amyloid — Tau — CSF — Brain volume measurements — Cognitive function measurements — Metabolomics — Biomarkers | |
Identifiers | PMID: 31078433 | |
Full text |
![]() ![]() Other version: https://www.sciencedirect.com/science/article/pii/S1552526019300743 |
|
Structures | ||
Research group | Troubles de mémoire et maladie d'Alzeimer (935) | |
Citation (ISO format) | KIM, Min et al. Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort. In: Alzheimer's & Dementia, 2019, vol. 15, n° 6, p. 817-827. doi: 10.1016/j.jalz.2019.03.004 https://archive-ouverte.unige.ch/unige:132383 |